USP Proposal on Temperature Control During Storage and Distribution
The USP has published a so called stimuli article that is intended to provide a proposal to revise an existing USP monograph.
The article provides a brief overview of drug product stability studies and practices with focus on temperature control during storage and distribution. The authors state that "recent stability studies support redefining controlled room temperature (CRT) by broadening the permitted range when appropriate for specific products. Currently marketed CRT products are not labeled to conform to a standard storage temperature range, as it is the case with cold chain products. CRT ranges on product labels can vary, even within an organization, and can differ from the USP definition."
The article concludes that stability studies historically support product storage in a relatively narrow range such as 20–25 or 15–25. Current studies support the approach to revise the current requirements and to allow store between 2 and 30 ºC. Such a change would have to be incorporated into USP general chapter "Packaging and Storage Requirements <659>. In addition, the authors propose "that both the primary packaging and the case labels list both the storage conditions (and distribution conditions if different) and typical excursion temperature data; e.g., store below 30, excursion to 40 for 1 month".
Please find the stimuli article in the Pharmacopeial Forum (PF). To read and download the article you need to register at no costs for the PF.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...